STAAR SURGICAL CO
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 312.6
- Dividend yield
- –
About Staar Surgical
Ophthalmic Goods, SIC 3851
STAAR Surgical Company designs, manufactures, and markets implantable lenses and delivery systems for ophthalmic surgery, specializing in phakic intraocular lenses used in refractive eye care. Its principal offerings comprise the EVO family of Implantable Collamer Lenses (ICLs), which include models such as EVO, EVO+, EVO Visian, and EVO Viva, designed to correct refractive vision conditions including myopia, astigmatism, and presbyopia without removing corneal tissue. The company sells its vision correction solutions globally to ophthalmic surgeons and patients seeking alternatives to eyeglasses or contact lenses.
The company distributes its products in more than 85 countries through direct representatives and independent distributors, generating the substantial majority of its sales internationally. STAAR maintains manufacturing, administrative, or research operations across the United States, Switzerland, and Japan, including facilities in Monrovia, Aliso Viejo, Tustin, Brügg, and Nidau. Its corporate headquarters is located in Lake Forest, California.
Summary of the business section of Staar Surgical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- STAAR SURGICAL CO
- Headquarters
- Monrovia, CA
- Address
- 1911 Walker Ave 91016
- Phone
- (626) 303-7902
- Employees
- 957, Jan 2, 2026
- Industry
- Ophthalmic Goods
- Incorporated in
- Delaware
- Fiscal year ends
- January 2
- Auditor
- BDO USA, P.C., Los Angeles, California
Stock & identifiers
- Ticker
- STAA
- Exchange
- Nasdaq
- Shares outstanding
- 50M, Aug 7, 2026
- Public float
- $883.91M, Jun 27, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-2 reverse, May 18, 1992
- SEC CIK
- 718937
- CUSIP
- 852312305
- ISIN
- US8523123052
- LEI
- 5299006LRHI7OJ8BY308
- EIN
- 95-3797439
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stephen C. Farrell | President & CEO, Director | 35,156 |
| Thomas G. Frinzi | President & CEO, Director | 70,519 |
| Magda Michna | Chief Development Officer | 40,243 |
| Warren Foust | President and CEO | 93,951 |
| Deborah J. Andrews | Chief Financial Officer & EVP | 38,910 |
| Nathaniel Sisitsky | Chief Legal Officer | 22,812 |
| Patrick F. Williams | Chief Financial Officer | 56,242 |
| Christopher Min Fang Wang | Director | 3,257,130 |
| Neal C. Bradsher | Director | 30,907,258 |
| Lilian Yansheng Zhou | Director | 8,101 |
| Wei Jiang | Director | 77,127 |
| Richard T. LeBuhn | Director | 22,130 |
| Arthur C. Butcher | Director | 9,549 |
| Lou Silverman | Director | 12,658 |
| Broadwood Partners, L.P. | Director | 39,830,560 |
| Elizabeth Yeu Lin | Director | 5,099 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Stephen CFarrell | $7.52M | $5.37M | $2.68M | $30 | $100 |
| FY2025 Thomas GFrinzi | $1.26M | $1.24M | $2.68M | $30 | $100 |
| FY2024 Thomas G. Frinzi | $7.82M | $2.75M | $2.56M | $31 | $95 |
| FY2024 Thomas GFrinzi | $7.82M | $2.75M | $2.56M | $31 | $95 |
| FY2023 Thomas G. Frinzi | $10.22M | $6.35M | $2.74M | $39 | $89 |
| FY2023 Thomas GFrinzi | $10.22M | $6.35M | $2.74M | $39 | $89 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of January 2, 2026, we had approximately 957 employees, of which 406 were employed outside the U.S.”
Corporate history
Events identified from SEC filings